Anti-cancer potential based on neutrophil activation
- Neutrophils activate innate and adaptive immune responses
- First line of defence against infection and inflammation
- Most abundant cell type in the circulation in man
- Many solid tumours, including NSCLC, are enriched with neutrophils
Enhances anti-tumour activity of immunosuppressive cells
- PMN-MDSCs1 are immunosuppressive neutrophils that are found in the tumour
- Play a key role in generating resistance to immunotherapies
- Associated with poor prognosis in many cancers
- IgA can cause PMN-MDSCs to become tumoricidal
Multiple effector functions
- Neutrophils have several direct effector functions including ADCC, ROS2 production and NETosis
- Anti-tumour antigen IgA delivers robust anti-tumour efficacy in vivo
- IgA binds tumour cells
- Tumour cell bound IgA attract and activate neutrophils and PMN-MDSCs
- Activated neutrophils and PMN-MDSCs kill tumour cells
- IgA activated neutrophils attract new neutrophils
to tumour - Neutrophils cross talk to other cancer fighting immune cells including T cells and macrophages
